Biotechnology News and Research

RSS

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.

30 Mar 2015

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.

30 Mar 2015

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI).

30 Mar 2015

MDC scientists find solution to increase efficiency of precise genetic modifications

CRISPR-Cas9 is a powerful new tool for editing the genome. For researchers around the world, the CRISPR-Cas9 technique is an exciting innovation because it is faster and cheaper than previous methods. Now, using a molecular trick, Dr. Van Trung Chu and Professor Klaus Rajewsky of the Max Delbrück Center for Molecular Medicine Berlin-Buch and Dr. Ralf Kühn, MDC and Berlin Institute of Health, have found a solution to considerably increase the efficiency of precise genetic modifications by up to eightfold.

30 Mar 2015

Iron oxide nanoparticles selectively target cell surface markers in tumor microenvironments

Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells.

30 Mar 2015

Mitochondrial DNA movement: an interview with Professor Jiri Neuzil, Griffith University

According to our understanding, mitochondria undergo cycles of fusion-fission, i.e. they divide within the constraints of a cell and, upon cell division, each of the two daughter cells gets its ‘share’ of mitochondria.

29 Mar 2015

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration.

29 Mar 2015

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus.

27 Mar 2015

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC). The current document is the first revision of the original guidelines published in 2009.

26 Mar 2015

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.

26 Mar 2015

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state--may better model the genetic contributions to each patient's particular disease. In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer.

26 Mar 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress.

25 Mar 2015

Marken secures Best Life Science Logistics Provider award

Marken announced today that they won the pharmaceutical clinical research industry award of Best Life Science Logistics Provider at the 5th Annual BioPharma Asia Industry Awards. The award was announced at a dinner and ceremony held in conjunction with the BioPharma Asia conference in Singapore, drawing an annual attendance of 1600.

25 Mar 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.

25 Mar 2015

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015.

24 Mar 2015

Biologists identify new mechanisms linked to progression of aggressive form of dementia

Research by biologists at the University of York has identified new mechanisms potentially driving progression of an aggressive form of dementia.

23 Mar 2015

TGAC plans to use miniaturised sequencing device to conduct live environmental surveillance

As one of the first research Institutes to take part in the MinION Access Programme (MAP) for portable DNA sequencing, introduced by Oxford Nanopore Technologies, The Genome Analysis Centre (TGAC)'s task force share their experience of the ground breaking trial so far.

From Oxford Nanopore Technologies 23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Biotechnology News and Research

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

MDC scientists find solution to increase efficiency of precise genetic modifications

Iron oxide nanoparticles selectively target cell surface markers in tumor microenvironments

Mitochondrial DNA movement: an interview with Professor Jiri Neuzil, Griffith University

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

New Ebola vaccine shows promise in first phase 1 clinical trial

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Marken secures Best Life Science Logistics Provider award

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

TxCell to present at upcoming US and French investment conferences

Biologists identify new mechanisms linked to progression of aggressive form of dementia

TGAC plans to use miniaturised sequencing device to conduct live environmental surveillance

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News